Inspire Medical Systems, Inc. INSP

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.

• Zacks Investment Research 23 sept

  Here's Why You Should Retain INSP Stock in Your Portfolio for Now

  Inspire Medical Systems is building momentum around its fifth-generation Inspire V system with expanding clinical evidence and improving reimbursement clarity across all six WISeR states. However, Q2 revenues declined 7.6% to $200.6M due to persistent coding disruption, and GLP-1 therapy adoption poses a risk to near-term procedure volumes. The company faces execution risks in translating patient-flow initiatives into sustained growth.

  

• Zacks Investment Research 18 sept

  Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

  West Pharmaceutical Services (WST) is well-positioned for growth driven by strong demand for high-value products (HVPs), expanding biologics exposure, and regulatory-driven Annex 1 conversions. The company expects about 200 basis points of revenue growth from Annex 1 upgrades in 2026. However, weak West Vantage segment performance due to a cyber incident and commodity inflation remain near-term concerns. The stock has gained 33.1% year-to-date.

  

• Zacks Investment Research 2 sept

  Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report?

  Inspire Medical Systems (INSP) reported Q2 2026 earnings that beat estimates with adjusted EPS of 14 cents versus expected loss of 22 cents, and raised full-year 2026 guidance. However, U.S. revenues declined 9.6% year-over-year due to coding and reimbursement challenges, partially offset by strong 33.6% international revenue growth. The stock has declined 4.1% since earnings despite the Zacks Rank #1 (Strong Buy) rating.

  

• GlobeNewswire Inc. 22 jul

  Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors

  Casey M. Tansey, a long-serving board member of Inspire Medical Systems who led the company's Series A financing in 2007 as a representative of U.S. Venture Partners, is retiring from the board effective July 30, 2026. CEO Tim Herbert praised Tansey's contributions and mentorship throughout the company's founding, IPO, and growth phases. Inspire plans to announce a replacement director soon.

  

• GlobeNewswire Inc. 16 jun

  Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study

  Inspire Medical Systems presented new clinical data at SLEEP 2026 demonstrating the effectiveness of its Inspire V hypoglossal nerve stimulation system for obstructive sleep apnea treatment. Key findings include significant reductions in hypoxic burden, improved cardiovascular outcomes compared to CPAP therapy, and higher patient adherence rates. The company also published studies identifying predictors for therapy eligibility and presented results from its 5,000-patient ADHERE registry showing 62% median AHI reduction.